Pharmaceutical Statistics高引用文章

• Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point

  引用次数：16

• On estimands and the analysis of adverse events in the presence of varying follow-up times within the benefit assessment of therapies

  引用次数：12

• Treatment effect quantification for time-to-event endpoints-Estimands, analysis strategies, and beyond

  引用次数：11

• Response-adaptive designs for binary responses: How to offer patient benefit while being robust to time trends?

  引用次数：8

• Some statistical considerations in the clinical development of cancer immunotherapies

  引用次数：8

• Propensity-score-based priors for Bayesian augmented control design

  引用次数：7

• Effect of heteroscedasticity between treatment groups on mixed-effects models for repeated measures

  引用次数：6

• Propensity score matched augmented controls in randomized clinical trials: A case study

  引用次数：6

• Better decision making in drug development through adoption of formal prior elicitation

  引用次数：5

• BOIN-ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes

  引用次数：5